Skip to main content
OpenTrials

Clinical trial discovery

Find Clinical Trials

Search studies by condition, treatment, location, eligibility, or trial identifier.

Showing 1–17 of 17 trials

Active filters

Clinical trials found

Published and searchable clinical trials

Searching for clinical trials...
Completed

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Fayetteville, Arkansas, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Anaheim, California, United States
View all 57 locations
View Trial Details
Completed

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Colorado Springs, Colorado, United States
  • GSK Investigational Site Longmont, Colorado, United States
  • GSK Investigational Site Doral, Florida, United States
  • GSK Investigational Site Miami Lakes, Florida, United States
View all 53 locations
View Trial Details
Completed

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

NCT04318548

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Bell Gardens, California, United States
  • GSK Investigational Site Los Angeles, California, United States
  • GSK Investigational Site Oakland, California, United States
View all 53 locations
View Trial Details
Completed

Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults

NCT04502693

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Glendale, Arizona, United States
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Bell Gardens, California, United States
View all 112 locations
View Trial Details
Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Huntsville, Alabama, United States
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Anaheim, California, United States
View all 37 locations
View Trial Details
Completed

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Hialeah, Florida, United States
  • GSK Investigational Site Melbourne, Florida, United States
  • GSK Investigational Site Augusta, Kansas, United States
View all 32 locations
View Trial Details
Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Fremont, California, United States
View all 14 locations
View Trial Details
Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
View all 19 locations
View Trial Details
Completed

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

NCT01682876

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site Lake Mary, Florida, United States
  • GSK Investigational Site Marietta, Georgia, United States
View all 19 locations
View Trial Details
Completed

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Dothan, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
View all 56 locations
View Trial Details
Completed

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

NCT01165242

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Chandler, Arizona, United States
  • GSK Investigational Site Paramount, California, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site Sacramento, California, United States
View all 32 locations
View Trial Details
Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

NCT00454909

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Fairfield, California, United States
  • GSK Investigational Site Redwood City, California, United States
  • GSK Investigational Site Sacramento, California, United States
View Trial Details
Completed

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

NCT01641042

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Fremont, California, United States
  • GSK Investigational Site Hayward, California, United States
View all 16 locations
View Trial Details
Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Daly City, California, United States
  • GSK Investigational Site Fairfield, California, United States
  • GSK Investigational Site Redwood City, California, United States
  • GSK Investigational Site Sacramento, California, United States
View Trial Details